Thiamet G
Based on 48 publication(s) in Google Scholar
Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with Ki of 20 nM for human OGA.
For research use only. We do not sell to patients.
- Purity: 99.99%
- CAS No.: 1009816-48-1
- Formula: C9H16N2O4S
- Molecular Weight:248.30
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
3D Diverse Fragment Library
HY-L903
Publications Citing Use of MedChemExpress (MCE) Thiamet G
More- Drug Resist Updat. 2024 Sep 12:77:101150. [Abstract]
- Cell Mol Immunol. 2025 Jan;22(1):68-82. [Abstract]
- Cancer Res. 2025 Mar 14;85(6):1113-1129. [Abstract]
- Nat Commun. 2021 May 11;12(1):2672. [Abstract]
- Cell Death Differ. 2025 Oct 6. [Abstract]
- Cell Death Differ. 2025 Jul 11. [Abstract]
- Adv Sci (Weinh). 2025 Oct 14:e10662. [Abstract]
- Adv Sci (Weinh). 2024 Nov 28:e2407519. [Abstract]
- Nat Chem Biol. 2022 Oct;18(10):1087-1095. [Abstract]
- Leukemia. 2022 Apr;36(4):1150-1159. [Abstract]
- Theranostics. 2020 Jun 1;10(16):7178-7192. [Abstract]
- J Adv Res. 2025 Sep 4:S2090-1232(25)00678-2. [Abstract]
- J Biomed Sci. 2022 Feb 14;29(1):13. [Abstract]
- Redox Biol. 2021 Jul:43:101994. [Abstract]
- J Hazard Mater. 2024 Dec 5:480:135952. [Abstract]
- Cancer Lett. 2024 May 1:589:216819. [Abstract]
- Burns Trauma. 2021 Oct 8:9:tkab031. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Int J Biol Macromol. 2025 Feb 11:140925. [Abstract]
- Acta Pharmacol Sin. 2025 Jul;46(7):2041-2055. [Abstract]
- EMBO Mol Med. 2022 Jan 11;14(1):e14678. [Abstract]
- NPJ Parkinsons Dis. 2026 Mar 28.
- Free Radic Biol Med. 2025 Oct 25.
- Clin Sci. 2025 Oct 22;139(20):1163-1185. [Abstract]
- Cell Rep. 2021 Sep 21;36(12):109739. [Abstract]
- Neurotherapeutics. 2021 Jan;18(1):340-363. [Abstract]
- Cell Rep. 2019 Aug 27;28(9):2386-2396.e5. [Abstract]
- Clin Transl Med. 2024 Oct;14(10):e70037. [Abstract]
- Clin Transl Med. 2024 Jan;14(1):e1531. [Abstract]
- Mol Med. 2024 Oct 18;30(1):180. [Abstract]
- EMBO Rep. 2021 Jun 4;22(6):e51649. [Abstract]
- Int J Oncol. 2023 Aug;63(2):90. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115158. [Abstract]
- Mol Oncol. 2025 Dec 30. [Abstract]
- Sci Rep. 2025 May 29;15(1):18853. [Abstract]
- J Biol Chem. 2024 May;300(5):107270. [Abstract]
- J Biol Chem. 2019 Nov 8;294(45):16620-16633. [Abstract]
- Cell Signal. 2021 Jul:83:110002. [Abstract]
- Mol Cell Pediatr. 2026 Feb 10;13(1):5. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328(6):G746-G759. [Abstract]
- J Cancer Res Clin Oncol. 2023 Jul;149(8):5255-5263. [Abstract]
- Toxicon. 2026 Apr 1:273:109018. [Abstract]
- Biochem Biophys Res Commun. 2024 Dec 5:742:151150. [Abstract]
- In Vitro Cell Dev Biol Anim. 2022 May;58(5):408-418. [Abstract]
- bioRxiv. 2025 Dec 11.
- University of Califomia San Francisco. 2025.
- bioRxiv. 2025 March 19.
- bioRxiv. 2025 Mar 13:2025.03.11.642699. [Abstract]
Customer Validation & Images
-
IP
-
Gel Electrophoresis
-
Gel Electrophoresis
-
Gel Electrophoresis
-
IP
Biological Activity
Ki: 20 nM (Human OGA)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PC-12 | EC50 |
30 nM
Compound: thiamet-G
|
Induction of O-GlcNAc level in NGF-differentiated rat PC12 cells after 24 hrs by densitometric analysis
Induction of O-GlcNAc level in NGF-differentiated rat PC12 cells after 24 hrs by densitometric analysis
|
[PMID: 18587388] |
Thiamet G (1 μM) induces a clear increase in the accumulation of O-GlcNAcylated proteins of ATDC5 cells. O-GlcNAc accumulation induced by Thiamet G also evokes a clear increase in the activity of these MMPs. Thiamet G (1 μM) induces the phosphorylation of JNK, ERK, and p38 but not phosphorylation of Akt[2]. Thiamet G (0.1-10 μM) does not significantly affect the cell viability. Thiamet G decreases phosphorylation of tau and alters the microtubule dynamics[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Thiamet G (20 mg/kg, i.p.) increases O-GlcNAc levels in brain, liver, and knee of the C57BL/6 mice in a dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1009816-48-1
-
Appearance Solid
-
Molecular Weight 248.30
-
Formula C9H16N2O4S
-
Color White to light yellow
-
SMILES
O[C@H]1[C@H](O)[C@@]2([H])N=C(NCC)S[C@@]2([H])O[C@@H]1CO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (48)
-
Journal Impact Factor
-
Most Recent
-
Drug Resist Updat
O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma. [Abstract]2024 Sep 12:77:101150. PMID: 39276723 -
Cell Mol Immunol
Dynamic O-GlcNAcylation governs long-range chromatin interactions in V(D)J recombination during early B-cell development. [Abstract]2025 Jan;22(1):68-82. PMID: 39627609 -
Cancer Res
MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma. [Abstract]2025 Mar 14;85(6):1113-1129. PMID: 39804969 -
Nat Commun
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. [Abstract]2021 May 11;12(1):2672. PMID: 33976130
Thiamet G purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 May 11;12(1):2672. [Abstract]
MDA-MB-231 and HCC1806 cells were treated with TM (2.5 μg/ml), Thiamet G (50 μM), and PUGNAc (100 μM) for 24 h.
Thiamet G purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 May 11;12(1):2672. [Abstract]
The indicated cell lines were treated with N-linked glycosylation inhibitors TM (2.5 μg/ml), SW (5 μg/ml), and DMJ (10 μg/ml), or O-linked glycosylation inhibitors Thiamet G (50 μM) and PUGNAc (100 μM) for 24 h.
-
Cell Death Differ
O-GlcNAcylation of UGDH regulates its activity and remodels the extracellular matrix to facilitate tumor growth. [Abstract]2025 Oct 6. PMID: 41053177
Thiamet G purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2025 Oct 6. [Abstract]
Analysis of UGDH glycosylation in HEK293T cells overexpressing Flag-tagged UGDH under co-transfection of HA-OGT or TMG treatment (50 μM; 48 h).
-
Cell Death Differ
GLUL mediates FOXO3 O-GlcNAcylation to regulate the osteogenic differentiation of BMSCs and senile osteoporosis. [Abstract]2025 Jul 11. PMID: 40646162 -
Adv Sci (Weinh)
ACE-mediated Glycosylation Stabilizes PSAP To Promote GPR37-dependent Macrophage-Nucleus Pulposus Cells Crosstalk and TGFβ Signaling in Alleviating Intervertebral Disc Degeneration. [Abstract]2025 Oct 14:e10662. PMID: 41085015 -
Adv Sci (Weinh)
Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage. [Abstract]2024 Nov 28:e2407519. PMID: 39605300
Thiamet G purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 28:e2407519. [Abstract]
HUCCT1-TRCs or RBE-TRCs were treated with TM (2.5 μg mL−1) or TG (Thiamet G) (50 μm) for 48 h.
-
Nat Chem Biol
2022 Oct;18(10):1087-1095. PMID: 35879546 -
Leukemia
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases. [Abstract]2022 Apr;36(4):1150-1159. PMID: 34997181 -
Theranostics
Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. [Abstract]2020 Jun 1;10(16):7178-7192. PMID: 32641986
Thiamet G purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 1;10(16):7178-7192. [Abstract]
TMG reduced gemcitabine induced apoptosis in L3.6pl while show no difference in TBO368. Cells were treated as indicated for 48 h and 72 h, in L3.6pl and TBO368, respectively. TMG (Thiamet G), 5 µM.
-
J Adv Res
2025 Sep 4:S2090-1232(25)00678-2. PMID: 40914422 -
J Biomed Sci
O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. [Abstract]2022 Feb 14;29(1):13. PMID: 35164752 -
Redox Biol
Hypoxic acclimation improves cardiac redox homeostasis and protects heart against ischemia-reperfusion injury through upregulation of O-GlcNAcylation. [Abstract]2021 Jul:43:101994. PMID: 33964586
Thiamet G purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Jul:43:101994. [Abstract]
Representative blots of O-GlcNAc modified G6PDH in the mouse hearts with indicated treatments,mice were treated by intraperitoneal injection with alloxan (ALX, 100 mg/kg; Sigma) or Thiamet-G (TMG, 20 mg/kg; MCE) at 6 h before cardiac I/R surgery
-
J Hazard Mater
Low-dose deoxynivalenol exposure triggers hepatic excessive ferritinophagy and mitophagy mitigated by hesperidin modulated O-GlcNAcylation. [Abstract]2024 Dec 5:480:135952. PMID: 39341193 -
Cancer Lett
Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer. [Abstract]2024 May 1:589:216819. PMID: 38522775 -
Burns Trauma
Inhibiting Hyper-O-GlcNAcylation of c-Myc accelerate diabetic wound healing by alleviating keratinocyte dysfunction. [Abstract]2021 Oct 8:9:tkab031. PMID: 34646892 -
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Int J Biol Macromol
Buckwheat protein-derived peptide ameliorates insulin resistance by directing O-linked N-acetylglucosamine transferase to regulate the SIRT1/PGC1α pathway. [Abstract]2025 Feb 11:140925. PMID: 39947565 -
Acta Pharmacol Sin
Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway. [Abstract]2025 Jul;46(7):2041-2055. PMID: 39984622 -
EMBO Mol Med
Inhibition of O-GlcNAcylation protects from Shiga toxin-mediated cell injury and lethality in host. [Abstract]2022 Jan 11;14(1):e14678. PMID: 34842355 -
-
-
Clin Sci
Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics. [Abstract]2025 Oct 22;139(20):1163-1185. PMID: 41082631 -
Cell Rep
DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation. [Abstract]2021 Sep 21;36(12):109739. PMID: 34551297 -
Neurotherapeutics
2021 Jan;18(1):340-363. PMID: 33258073 -
Cell Rep
MAVS O-GlcNAcylation Is Essential for Host Antiviral Immunity against Lethal RNA Viruses. [Abstract]2019 Aug 27;28(9):2386-2396.e5. PMID: 31461653 -
Clin Transl Med
O-GlcNAcylation promotes malignancy and cisplatin resistance of lung cancer by stabilising NRF2. [Abstract]2024 Oct;14(10):e70037. PMID: 39358921 -
Clin Transl Med
Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor. [Abstract]2024 Jan;14(1):e1531. PMID: 38214432 -
Mol Med
New perspectives on YTHDF2 O-GlcNAc modification in the pathogenesis of intervertebral disc degeneration. [Abstract]2024 Oct 18;30(1):180. PMID: 39425013 -
EMBO Rep
O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity. [Abstract]2021 Jun 4;22(6):e51649. PMID: 33855783 -
Int J Oncol
O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway. [Abstract]2023 Aug;63(2):90. PMID: 37350405 -
Int Immunopharmacol
Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis. [Abstract]2025 Sep 23:162:115158. PMID: 40602265 -
Mol Oncol
Dammarenediol II enhances etoposide-induced apoptosis by targeting O-GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer. [Abstract]2025 Dec 30. PMID: 41466540 -
Sci Rep
GLUT1-mediated HMGB1 O-GlcNAcylation drives hyperglycemia-Induced neutrophil extracellular trap networks formation via TLR4 signaling and exacerbates fibroblast inflammation. [Abstract]2025 May 29;15(1):18853. PMID: 40442314 -
J Biol Chem
2024 May;300(5):107270. PMID: 38599381 -
J Biol Chem
O-GlcNAcylation of Thr12/Ser56 in short-form O-GlcNAc transferase (sOGT) regulates its substrate selectivity. [Abstract]2019 Nov 8;294(45):16620-16633. PMID: 31527085 -
Cell Signal
2021 Jul:83:110002. PMID: 33823241 -
Mol Cell Pediatr
O-GlcNAcylation expression predicts a favorable prognosis and mitigates malignant phenotypes via MYCN suppression in neuroblastoma. [Abstract]2026 Feb 10;13(1):5. PMID: 41665859 -
Am J Physiol Gastrointest Liver Physiol
Glucose metabolism through the hexosamine biosynthetic pathway drives hepatic de novo lipogenesis via promoting N-linked protein glycosylation. [Abstract]2025 Jun 1;328(6):G746-G759. PMID: 40331866 -
J Cancer Res Clin Oncol
2023 Jul;149(8):5255-5263. PMID: 36401094 -
Toxicon
Toosendanin sensitizes hepatocyte ferroptosis via dual inhibition of Nrf2 O-GlcNAcylation and USP7-driven deubiquitination. [Abstract]2026 Apr 1:273:109018. PMID: 41628670 -
Biochem Biophys Res Commun
2024 Dec 5:742:151150. PMID: 39657353 -
In Vitro Cell Dev Biol Anim
The interaction of O-GlcNAc-modified NLRX1 and IKK-α modulates IL-1β expression in M1 macrophages. [Abstract]2022 May;58(5):408-418. PMID: 35513753 -
-
-
-
bioRxiv
2025 Mar 13:2025.03.11.642699. PMID: 40161616
Solvent & Solubility
DMSO : 233.33 mg/mL (939.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 50 mg/mL (201.37 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (201.37 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
All enzymatic assays are performed in triplicate at 37°C using 4-methylumbelliferyl N-acetyl-β-d-glucosaminide dehydrate as substrate. 1 nM of purified OGA is incubated with the compounds for 5 min, and then 0.2 mM of the substrate is added. The liberation of 4-methylumbellifery is monitored by kinetic reading at excitation/emission 355/460 nm using a Tecan M200 plate in a mode of 60 s/cycle and 15 cycles in total.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Jurkat cells are seeded at 6000 cells/well in a 96-well plate, and 12 h later, cells are treated with compounds for the indicated time. Cell viability is determined by XTT assay.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
For the Thiamet G dose dependence study, six 23-day-old male C57BL/6 mice receive single intraperitoneal injections of either 0, 10, 20, 100, 200, or 500 mg/kg of Thiamet G dissolved in PBS and then are euthanized 8 h later to evaluate the O-GlcNAc levels in different tissues (brain, liver, muscle, and knee). The time of sacrifice is chosen on the basis of previously published data on Thiamet G in rodents, which demonstrates that the peak level of O-GlcNAc proteins following administration of the drug is achieved after 8-10 h. Tissues are collected immediately after sacrifice, flash-frozen in liquid nitrogen, and stored at −80°C until required for use.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yuzwa SA, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012 Feb 26;8(4):393-9. [Content Brief]
[2]. Andrés-Bergós J, et al. The increase in O-linked N-acetylglucosamine protein modification stimulates chondrogenic differentiation both in vitro and in vivo. J Biol Chem. 2012 Sep 28;287(40):33615-28. [Content Brief]
[3]. Ding N, et al. Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent NSC 125973. Biochem Biophys Res Commun. 2014 Oct 24;453(3):392-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.0274 mL | 20.1369 mL | 40.2739 mL | 100.6847 mL |
| 5 mM | 0.8055 mL | 4.0274 mL | 8.0548 mL | 20.1369 mL | |
| 10 mM | 0.4027 mL | 2.0137 mL | 4.0274 mL | 10.0685 mL | |
| 15 mM | 0.2685 mL | 1.3425 mL | 2.6849 mL | 6.7123 mL | |
| 20 mM | 0.2014 mL | 1.0068 mL | 2.0137 mL | 5.0342 mL | |
| 25 mM | 0.1611 mL | 0.8055 mL | 1.6110 mL | 4.0274 mL | |
| 30 mM | 0.1342 mL | 0.6712 mL | 1.3425 mL | 3.3562 mL | |
| 40 mM | 0.1007 mL | 0.5034 mL | 1.0068 mL | 2.5171 mL | |
| 50 mM | 0.0805 mL | 0.4027 mL | 0.8055 mL | 2.0137 mL | |
| 60 mM | 0.0671 mL | 0.3356 mL | 0.6712 mL | 1.6781 mL | |
| 80 mM | 0.0503 mL | 0.2517 mL | 0.5034 mL | 1.2586 mL | |
| 100 mM | 0.0403 mL | 0.2014 mL | 0.4027 mL | 1.0068 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz